Mog Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MOG (Myelin Oligodendrocyte Glycoprotein) is a gene that encodes a transmembrane protein expressed exclusively in the central nervous system (CNS) myelin. It is a minor component of myelin (0.1-0.5% of total myelin protein) but plays critical roles in immune recognition and the maintenance of myelin integrity. MOG is a well-known autoantigen in multiple sclerosis and is used extensively in experimental autoimmune encephalomyelitis (EAE) models. [1]
| Attribute | Value | [2]
|-----------|-------| [3]
| Gene Symbol | MOG | [4]
| Full Name | Myelin Oligodendrocyte Glycoprotein |
| Chromosomal Location | 6p22.2 |
| NCBI Gene ID | 4340 |
| Ensembl ID | ENSG00000137355 |
| UniProt ID P20916 |
| OMIM ID 159445 |
MOG is a type I transmembrane glycoprotein with an immunoglobulin-like domain. Its functions include:
MOG is expressed exclusively by mature oligodendrocytes in the CNS and appears after active myelination begins.
MOG is one of the most studied autoantigens in MS:
A distinct autoimmune disorder characterized by:
Unlike MS, MOGAD typically responds well to immunotherapy and has a better prognosis.
MOG expression is restricted to:
Expression is developmentally regulated, appearing after MBP and PLP expression peaks.
The study of Mog Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Linington C, et al. T cells specific for the myelin oligodendrocyte glycoprotein cause demyelinating disease in rats. Eur J Immunol. 1988. ↩︎
Reindl M, et al. MOG antibodies in disease: a systematic review and combined analysis. Neurology. 2020. ↩︎
Hohlfeld R, et al. The role of MOG in multiple sclerosis and experimental autoimmune encephalomyelitis. Lancet Neurol. 2021. ↩︎
Jurynczyk M, et al. MOG antibody disease: clinical phenotype, treatment and outcomes. J Neurol Neurosurg Psychiatry. 2021. ↩︎